Partnership Aims to Advance Malaria Vaccine R&D - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Partnership Aims to Advance Malaria Vaccine R&D


ePT--the Electronic Newsletter of Pharmaceutical Technology

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals have announced a follow-on collaboration to advance the development of malaria vaccines and new vaccine delivery technologies.

The companies will test whether combining genetically engineered DNA with electroporation, a new vaccine delivery technology, can induce a suitable immune response in humans to protect against malaria parasite infection.

Using controlled electrical impulses, electroporation creates temporary pores in a cell membrane that will allow for uptake of the synthetic DNA. The DNA instructions can then be used by the cell to produce proteins that mimic the presence of the malaria pathogen. Researchers hope the technology will induce an immune response that provides protection against malaria.

Dr. J. Joseph Kim, President and CEO of Inovio, said, in a statement, “Our synthetic vaccine platform has produced vaccine candidates against HPV, HIV, and influenza targets that have generated potent T cell immune responses observed in human clinical studies. Using the same platform technology, we have now generated encouraging data with preclinical testing of our malaria antigen plasmids.” Human clinical trials will begin in early 2014, where the vaccine technology will be tested in approximately 30 individuals. Volunteers will receive the vaccine and then be exposed to the malaria parasite to see whether infection is prevented.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here